IDT Australia last week opened
a new CMAX purpose-built clinical
trial facility in Adelaide.
Projects to be undertaken there
include a second study investigating
a wearable device to provide
an early warning system for
hypoglycaemic events in diabetic
patients, and a gene therapy
study developed by a Japanese
biopharmaceutical company for
the treatment of peripheral arterial
disease.The above article was sent to subscribers in Pharmacy Daily's issue from 02 May 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 02 May 16
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.